1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Two structural conditions align: (1) a multi-year price band exists where the stock has, on at least two separated occasions, stopped advancing and pulled back, and (2) current price is back inside or just below that zone, near the top of its recent trading range. The retest is happening at a level the stock has reached before and turned away from.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
Dividends view
Last Ex-Dividend
Apr 29, 2024
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
48.31BEUR
vs all stocks (USD)
Updated Jul 14, 2026
Revenue (TTM)
47.64BEUR
vs all stocks (USD)
Updated Jul 14, 2026
Profit Margin
-6.17%
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is in the bottom 5% of Drug Manufacturers General peersSignificant
Operating margin: 0.16Industry P5: 0.20
Profit margin is in the bottom 5% of Drug Manufacturers General peersSignificant
Profit margin: -0.06Industry P5: 0.13
Return on equity is in the bottom 5% of Drug Manufacturers General peersSignificant
Return on equity: -0.08Industry P5: 0.12
Return on assets is in the bottom 5% of Drug Manufacturers General peersSignificant
CompanyGraph